Abstract: Provided herein are compositions and methods relating to oral care compositions with improved taste. One such method includes providing an oral care composition comprising a metal salt, a peroxide, an antimicrobial agent, a bad breath reduction agent, a surfactant, or a combination thereof and adding to the oral care composition a TRPV1 activator and/or vanitrope.

Abstract: The invention is drawn to fluid concentrate formulations of fatty acid monoethanolamides comprising (a) about 71-76% by weight of one or more C8-C22 fatty acid monoethanolamides, (b) about 15-17% by weight of water, and (c) about 10-12% by weight of one or more hydrotropes, based on the fluid formulation, wherein the fluid formulation is homogeneous, pumpable and color stable at a temperature of less than 55° C. A preferred embodiment is drawn to fluid concentrate formulations of cocamide monoethanolamide (CMEA) consisting of (a) about 71-76% by weight of CMEA, (b) about 15-17% by weight of water, and (c) about 10-12% by weight of glycerol, based on the fluid formulation. Methods of preparing the fluid concentrate formulations mulations are also disclosed. The fluid concentrate formulations of fatty acid monoethanolamides are useful in the preparation of cosmetic and pharmaceutical compositions.

Abstract: An animal chew including a surface comprising a base composition, wherein the animal chew exhibits a hardness in the range of Shore 70A to Shore 70D as measured by ASTM D2240-05 (2010) and a flexural modulus in the range of 50×103 psi to 500×103 psi as measured by ASTM D790-10 and Ascophyllum nodosum applied onto at least a portion of the surface of the animal chew, wherein the Ascophyllum nodosum is present in an amount of 0.1% by weight to 5.0% by weight of the animal chew. At least 10% by weight of the total amount of the Ascophyllum nodosum present in the animal chew may be applied to the animal chew surface.

Abstract: Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.

Abstract: The present invention relates to methods of making a powder for inhalation comprising a first step of mixing particles of a force-controlling agent selected from the group consisting of phospholipids, titanium dioxide, aluminum dioxide, silicon dioxide, starch, and salts of fatty acids, with particles of one or more pharmacologically active materials, wherein the mixing is achieved by one or more of the processes of sieving, mixing or blending, and wherein the mixing results in the particles of the force-controlling agent being disposed on the surface of the particles of the one or more pharmacologically active materials as either a particulate coating or as a continuous or discontinuous film.

Abstract: An environmentally- and user-friendly, aqueous antimicrobial solution comprising effective amounts of hydrogen peroxide, glycolic acid, and at least one antimicrobially-active solvent chosen from benzyl alcohol and phenoxyethanol; concentrated versions of same; kits that can be used to make same; wipes containing same; and the use of same in a method of antimicrobial treatment of a surface contaminated with a microorganism (e.g. bacterial or fungal spore such as C. Difficile).

Abstract: The present invention relates to a pharmaceutical composition for inhalation. The invention is further directed to a method for setting the performance characteristics of such a pharmaceutical composition and the use of such a composition in the treatment of asthma, COPD, allergies, infectious diseases and diseases of the cardiovascular system.

Abstract: A spray-chilled particulate delivery system that has a crystalline matrix structure and includes a volatile hydrophobic active ingredient and a carrier material of erythritol, mannitol and mixtures thereof 75% or more of the carrier material, relative to the total weight of the carrier material, is in crystalline form. The system is prepared by a process that includes the steps of forming a melt of the carrier material, incorporating a volatile hydrophobic active ingredient into the melt, forming a melt-mixture comprising an emulsion, dispersion or suspension of the volatile hydrophobic active ingredient in the melt, forming discrete particles of the melt mixture, and cooling the discrete particles.

Abstract: An anhydrous liquid antiperspirant/deodorant composition comprising a carrier comprising a cation and/or zwitterion and a hydrogen bond donor, wherein an amount of carrier is greater than an amount of any other material in the composition, and an antiperspirant active. This represents a new delivery form for antiperspirant actives and/or deodorant actives.

Abstract: The present invention utilizes a nano-coating of an oxide such as silica, a silicate or another effective oxide on a surface to accelerate blood clotting in mammalian animals. The hemostatic layer has a thickness that is effective for the hemostasis, yet can be made thin enough to result in a resorbable film which can either be applied to a biocompatible or resorbable device that can be used in surgical applications as well as in topical applications such as trauma.

Abstract: A comb-like surfactant polymer for changing the surface properties of biomaterials is described. The surfactant polymer comprises a polymeric backbone of repeating monomeric units having functional groups for chemically attaching to side chains, a plurality of hydrophobic side chains attached to the backbone via the functional groups and a plurality of hydrophilic side chains chemically attached via functional groups to the polymeric backbone. The hydrophilic side chains providing anti-thrombogenic properties to the surfactant. An antimicrobial agent selectively attached to some hydrophilic side chains thereby providing additional antimicrobial properties to the surfactant. The surfactant polymer may be applied to the surface of medical devices to reduce the surfaces thrombogenicity and decrease the number of microorganisms on the surface.

Abstract: An inhalable medicament is provided, in particular a new solid-state form of tiotropium bromide. The medicament can be in the form of solid amorphous particles containing an intimate admixture of tiotropium bromide together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least ?50° C., such as a sugar and/or sugar alcohol.

Abstract: A hemostatic textile material to stop bleeding comprising a dialdehyde cellulose (DAC) carrier wherein the degree of oxidation of the dialdehyde cellulose varies from about 1.5% to 12%; and a blood coagulation factor selected from the group consisting of chitosan and gelatin; the blood coagulation factor being chemically immobilized thereon; and further optionally comprising a bacteriolytic agent selected from the group consisting of a lysozyme enzyme, silver nitrate, and chlorhexidine; and further optionally comprising a selected component that prevents hemolysis, the component selected from the group consisting of tranexamic acid or ?-aminocaproic acid chemically immobilized thereon.

Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.

Abstract: The subject invention relates to a skin cream that can be used to moisturize and rejuvenate skin that has been damaged by exposure to sunlight or which has simply been affected over the years by intrinsic aging. It inhibits the formation of wrinkles and in some cases reduces the depth of existing wrinkles or eliminates them entirely. This invention is based upon the discovery that alkyl lactates, such as ethyl lactate, can be used to improve the penetration of active ingredients in skin care formulations deep into lower layers of the skin tissue. The present invention more specifically discloses a topical formulation comprising ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, an alkyl lactate, and a pharmaceutically acceptable carrier.

Abstract: This invention is directed to advanced hemorrhage control wound dressings, and methods of using and producing same. The subject wound dressing is constructed from a non-mammalian material for control of severe 5 bleeding. The wound dressing for controlling severe bleeding is formed of a biomaterial comprising chitosan, a hydrophilic polymer, a polyacrylic polymer or a combination thereof, The kind of severe, life-threatening bleeding contemplated by this invention is typically of the type not capable of being stanched when a conventional gauze wound dressing is applied with conventional 10 pressure to the subject wound. The wound dressing being capable of substantially stanching the flow of the severe life-threatening bleeding from the wound by adhering to the wound site, to seal the wound, to accelerate blood clot formation at the wound site, to reinforce clot formation at the wound site and prevent bleed out from the wound site, and to substantially prohibit the flow of 15 blood out of the wound site.

Abstract: Embodiments of the invention relate to a method of making a mineral product. The method includes contacting a carboxylic acid and an inorganic mineral compound sufficient to form a solution, reacting the solution over a period of time sufficient to provide a mineral chelated compound, transferring the mineral chelated compound to one or more molds prior to the compound substantially solidifying and reducing the size of the mineral chelated compound sufficient to provide a rapidly soluble mineral chelated product.

Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.

Abstract: Pharmaceutical formulation in the form of compacts comprising A) an agglomerated excipient content composed of a1) 60-97% by weight of sugar or sugar alcohols, a2) 1-25% by weight of a disintegrant, selected from the group consisting of crospovidone, croscarmellose, sodium carboxymethylstarch and L-hydroxypropylcellulose, a3) 1-15% by weight of water-insoluble, film-forming polymers a4) 0-15% by weight of water-soluble polymers and a5) 0-15% by weight of further pharmaceutically customary excipients, the total of the components a1) to a5) being 100% by weight, B) at least one active ingredient, C) 0 to 10% by weight, based on the total amount of A) to D), of a lubricant or mold release agent, and D), if appropriate, further pharmaceutical excipients.

Abstract: A Natural oils composition for hardening and strengthening fingernails and toenails in which the natural oils contained therein exhibit ability to self polymerize into a solid film in the presence of oxygen. Oils of this invention are diluted with compatible solvents allowing penetration into the nail. Oils of this invention exhibit an Iodine Value greater than 140 grams of iodine absorbed per 100 grams of oil as measured under the prescribed conditions of a standard method described forthwith. Fingernail strengthening and conditioning compositions with antifungal properties are also disclosed.